Tomasz Huzarski1, Tomasz Byrski, Jacek Gronwald, Bohdan Górski, Pawel Domagala, Cezary Cybulski, Oleg Oszurek, Marek Szwiec, Karol Gugala, Malgorzata Stawicka, Zbigniew Morawiec, Tomasz Mierzwa, Hanna Janiszewska, Ewa Kilar, Elzbieta Marczyk, Beata Kozak-Klonowska, Monika Siolek, Dariusz Surdyka, Rafal Wisniowski, Michal Posmyk, Ping Sun, Jan Lubinski, Steven A Narod. 1. Tomasz Huzarski, Tomasz Byrski, Jacek Gronwald, Bohdan Górski, Pawel Domagała, Cezary Cybulski, Oleg Oszurek, and Jan Lubiński, Pomeranian Medical University, Szczecin; Marek Szwiec, Regional Oncology Center, Opole; Karol Gugała, District Specialist Hospital, Olsztyn; Malgorzata Stawicka, Regional Oncology Center, Poznań; Zbigniew Morawiec, Regional Oncology Center, Łódź; Tomasz Mierzwa, Regional Oncology Hospital; Hanna Janiszewska, Nicolaus Copernicus University, Bydgoszcz; Ewa Kilar, District Specialist Hospital, Świdnica; Elzbieta Marczyk, Regional Oncology Center, Kraków; Beata Kozak-Klonowska and Monika Siołek, Regional Oncology Center, Kielce; Dariusz Surdyka, St John's Cancer Center, Lublin; Rafal Wiśniowski, Regional Oncology Hospital, Bielsko Biała; Michal Posmyk, Regional Oncology Center, Białystok, Poland; and Ping Sun and Steven A. Narod, Women's College Research Institute, Toronto, Ontario, Canada.
Abstract
PURPOSE: To estimate 10-year overall survival (OS) rates for patients with early-onset breast cancer, with and without a BRCA1 mutation, and to identify prognostic factors among those with BRCA1-positive breast cancer. PATIENTS AND METHODS: A total of 3,345 women with stage I to III breast cancer, age ≤ 50 years, were tested for three founder mutations in BRCA1. Information on tumor characteristics and treatments received was retrieved from medical records. Dates of death were obtained from the vital statistics registry. Survival curves for the mutation-positive and -negative subcohorts were compared. Predictors of OS were determined using the Cox proportional hazards model. RESULTS: Of the 3,345 patients enrolled onto the study, 233 (7.0%) carried a BRCA1 mutation. The 10-year survival rate for mutation carriers was 80.9% (95% CI, 75.4% to 86.4%); for noncarriers, it was 82.2% (95% CI, 80.5% to 83.7%). The adjusted hazard ratio (HR) associated with carrying a BRCA1 mutation was 1.81 (95% CI, 1.26 to 2.61). Among BRCA1 carriers with a small (< 2 cm) node-negative tumor, the 10-year survival rate was 89.9%. Among BRCA1 mutation carriers, positive lymph node status was a strong predictor of mortality (adjusted HR, 4.1; 95% CI, 1.8 to 8.9). Oophorectomy was associated with improved survival in BRCA1 carriers (adjusted HR, 0.30; 95% CI, 0.12 to 0.75). CONCLUSION: The 10-year survival rate among women with breast cancer and a BRCA1 mutation is similar to that of patients without a BRCA1 mutation. Among women with a BRCA1 mutation, survival was much improved after oophorectomy.
PURPOSE: To estimate 10-year overall survival (OS) rates for patients with early-onset breast cancer, with and without a BRCA1 mutation, and to identify prognostic factors among those with BRCA1-positive breast cancer. PATIENTS AND METHODS: A total of 3,345 women with stage I to III breast cancer, age ≤ 50 years, were tested for three founder mutations in BRCA1. Information on tumor characteristics and treatments received was retrieved from medical records. Dates of death were obtained from the vital statistics registry. Survival curves for the mutation-positive and -negative subcohorts were compared. Predictors of OS were determined using the Cox proportional hazards model. RESULTS: Of the 3,345 patients enrolled onto the study, 233 (7.0%) carried a BRCA1 mutation. The 10-year survival rate for mutation carriers was 80.9% (95% CI, 75.4% to 86.4%); for noncarriers, it was 82.2% (95% CI, 80.5% to 83.7%). The adjusted hazard ratio (HR) associated with carrying a BRCA1 mutation was 1.81 (95% CI, 1.26 to 2.61). Among BRCA1 carriers with a small (< 2 cm) node-negative tumor, the 10-year survival rate was 89.9%. Among BRCA1 mutation carriers, positive lymph node status was a strong predictor of mortality (adjusted HR, 4.1; 95% CI, 1.8 to 8.9). Oophorectomy was associated with improved survival in BRCA1 carriers (adjusted HR, 0.30; 95% CI, 0.12 to 0.75). CONCLUSION: The 10-year survival rate among women with breast cancer and a BRCA1 mutation is similar to that of patients without a BRCA1 mutation. Among women with a BRCA1 mutation, survival was much improved after oophorectomy.
Authors: Amy P M Finch; Jan Lubinski; Pål Møller; Christian F Singer; Beth Karlan; Leigha Senter; Barry Rosen; Lovise Maehle; Parviz Ghadirian; Cezary Cybulski; Tomasz Huzarski; Andrea Eisen; William D Foulkes; Charmaine Kim-Sing; Peter Ainsworth; Nadine Tung; Henry T Lynch; Susan Neuhausen; Kelly A Metcalfe; Islay Thompson; Joan Murphy; Ping Sun; Steven A Narod Journal: J Clin Oncol Date: 2014-02-24 Impact factor: 44.544
Authors: Maria Kabisch; Justo Lorenzo Bermejo; Thomas Dünnebier; Shibo Ying; Kyriaki Michailidou; Manjeet K Bolla; Qin Wang; Joe Dennis; Mitul Shah; Barbara J Perkins; Kamila Czene; Hatef Darabi; Mikael Eriksson; Stig E Bojesen; Børge G Nordestgaard; Sune F Nielsen; Henrik Flyger; Diether Lambrechts; Patrick Neven; Stephanie Peeters; Caroline Weltens; Fergus J Couch; Janet E Olson; Xianshu Wang; Kristen Purrington; Jenny Chang-Claude; Anja Rudolph; Petra Seibold; Dieter Flesch-Janys; Julian Peto; Isabel dos-Santos-Silva; Nichola Johnson; Olivia Fletcher; Heli Nevanlinna; Taru A Muranen; Kristiina Aittomäki; Carl Blomqvist; Marjanka K Schmidt; Annegien Broeks; Sten Cornelissen; Frans B L Hogervorst; Jingmei Li; Judith S Brand; Keith Humphreys; Pascal Guénel; Thérèse Truong; Florence Menegaux; Marie Sanchez; Barbara Burwinkel; Frederik Marmé; Rongxi Yang; Peter Bugert; Anna González-Neira; Javier Benitez; M Pilar Zamora; Jose I Arias Perez; Angela Cox; Simon S Cross; Malcolm W R Reed; Irene L Andrulis; Julia A Knight; Gord Glendon; Sandrine Tchatchou; Elinor J Sawyer; Ian Tomlinson; Michael J Kerin; Nicola Miller; Christopher A Haiman; Fredrick Schumacher; Brian E Henderson; Loic Le Marchand; Annika Lindblom; Sara Margolin; Maartje J Hooning; Antoinette Hollestelle; Mieke Kriege; Linetta B Koppert; John L Hopper; Melissa C Southey; Helen Tsimiklis; Carmel Apicella; Seth Slettedahl; Amanda E Toland; Celine Vachon; Drakoulis Yannoukakos; Graham G Giles; Roger L Milne; Catriona McLean; Peter A Fasching; Matthias Ruebner; Arif B Ekici; Matthias W Beckmann; Hermann Brenner; Aida K Dieffenbach; Volker Arndt; Christa Stegmaier; Alan Ashworth; Nicholas Orr; Minouk J Schoemaker; Anthony Swerdlow; Montserrat García-Closas; Jonine Figueroa; Stephen J Chanock; Jolanta Lissowska; Mark S Goldberg; France Labrèche; Martine Dumont; Robert Winqvist; Katri Pylkäs; Arja Jukkola-Vuorinen; Mervi Grip; Hiltrud Brauch; Thomas Brüning; Yon-Dschun Ko; Paolo Radice; Paolo Peterlongo; Giulietta Scuvera; Stefano Fortuzzi; Natalia Bogdanova; Thilo Dörk; Arto Mannermaa; Vesa Kataja; Veli-Matti Kosma; Jaana M Hartikainen; Peter Devilee; Robert A E M Tollenaar; Caroline Seynaeve; Christi J Van Asperen; Anna Jakubowska; Jan Lubinski; Katarzyna Jaworska-Bieniek; Katarzyna Durda; Wei Zheng; Martha J Shrubsole; Qiuyin Cai; Diana Torres; Hoda Anton-Culver; Vessela Kristensen; François Bacot; Daniel C Tessier; Daniel Vincent; Craig Luccarini; Caroline Baynes; Shahana Ahmed; Mel Maranian; Jacques Simard; Georgia Chenevix-Trench; Per Hall; Paul D P Pharoah; Alison M Dunning; Douglas F Easton; Ute Hamann Journal: Carcinogenesis Date: 2015-01-13 Impact factor: 4.944
Authors: David D Stenehjem; Claire Telford; Sudhir K Unni; Hillevi Bauer; Amy Sainski; Rishi Deka; Marisa B Schauerhamer; Xiangyang Ye; Casey R Tak; Junjie Ma; Tapashi B Dalvi; Lia Gutierrez; James A Kaye; Jerzy E Tyczynski; Diana I Brixner; Joseph E Biskupiak Journal: Breast Cancer Res Treat Date: 2021-01-03 Impact factor: 4.872
Authors: C Villarreal-Garza; J N Weitzel; M Llacuachaqui; E Sifuentes; M C Magallanes-Hoyos; L Gallardo; R M Alvarez-Gómez; J Herzog; D Castillo; R Royer; Mohammad Akbari; F Lara-Medina; L A Herrera; A Mohar; S A Narod Journal: Breast Cancer Res Treat Date: 2015-02-26 Impact factor: 4.872
Authors: Adriana Valentini; Amy Finch; Jan Lubinski; Tomasz Byrski; Parviz Ghadirian; Charmaine Kim-Sing; Henry T Lynch; Peter J Ainsworth; Susan L Neuhausen; Ellen Greenblatt; Christian Singer; Ping Sun; Steven A Narod Journal: J Clin Oncol Date: 2013-08-26 Impact factor: 44.544
Authors: Adriana Valentini; Jan Lubinski; Tomasz Byrski; Parviz Ghadirian; Pal Moller; Henry T Lynch; Peter Ainsworth; Susan L Neuhausen; Jeffrey Weitzel; Christian F Singer; Olufunmilayo I Olopade; Howard Saal; Dominique Stoppa Lyonnet; William D Foulkes; Charmaine Kim-Sing; Siranoush Manoukian; Dana Zakalik; Susan Armel; Leigha Senter; Charis Eng; Eva Grunfeld; Anna M Chiarelli; Aletta Poll; Ping Sun; Steven A Narod Journal: Breast Cancer Res Treat Date: 2013-10-18 Impact factor: 4.872
Authors: Peter A Fasching; Siddhartha Yadav; Chunling Hu; Marius Wunderle; Lothar Häberle; Steven N Hart; Matthias Rübner; Eric C Polley; Kun Y Lee; Rohan D Gnanaolivu; Peyman Hadji; Hanna Hübner; Hans Tesch; Johannes Ettl; Friedrich Overkamp; Michael P Lux; Arif B Ekici; Bernhard Volz; Sabrina Uhrig; Diana Lüftner; Markus Wallwiener; Volkmar Müller; Erik Belleville; Michael Untch; Hans-Christian Kolberg; Matthias W Beckmann; André Reis; Arndt Hartmann; Wolfgang Janni; Pauline Wimberger; Florin-Andrei Taran; Tanja N Fehm; Diethelm Wallwiener; Sara Y Brucker; Andreas Schneeweiss; Andreas D Hartkopf; Fergus J Couch Journal: J Clin Oncol Date: 2021-03-29 Impact factor: 44.544